← Back to Screener
Oramed Pharmaceuticals Inc. (ORMP)
Price$3.71
Value ScoreC
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)22.25%
Price vs S&P 500 (4W)-9.28%
VGM Score54.42
Market Capitalization$151.84M
P/E Ratio (Annual)2.37x
Indicated Dividend Yield (Annual)0.00%
All Metrics
Book Value / Share (Quarterly)$5.82
P/TBV (Annual)0.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-9.52%
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)22.02%
Gross Margin (TTM)0.65%
Net Profit Margin (TTM)-838.40%
EPS (TTM)$2.59
10-Day Avg Trading Volume0.23M
EPS Excl Extra (TTM)$2.59
Revenue Growth (5Y)-5.83%
EPS (Annual)$1.51
ROI (Annual)32.07%
Gross Margin (Annual)0.65%
Net Profit Margin (5Y Avg)29.27%
Cash / Share (Quarterly)$1.61
P/E Basic Excl Extra (TTM)1.38x
P/E Normalized (Annual)2.37x
ROA (Last FY)27.74%
Revenue Growth TTM (YoY)-30.93%
EBITD / Share (TTM)$-0.34
ROE (5Y Avg)-1.74%
Operating Margin (TTM)-1070.36%
Cash Flow / Share (Annual)$-0.23
P/B Ratio0.64x
P/B Ratio (Quarterly)0.58x
Net Income / Employee (Annual)$4,926,900
EV / Revenue (TTM)58.67x
Net Interest Coverage (TTM)-2.84x
ROA (TTM)49.75%
EV / EBITDA (TTM)1.25x
EPS Incl Extra (Annual)$1.51
Current Ratio (Annual)6.98x
Quick Ratio (Quarterly)6.23x
3-Month Avg Trading Volume0.16M
52-Week Price Return72.56%
P/E Incl Extra (TTM)1.38x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.70
P/S Ratio (Annual)113.31x
Asset Turnover (Annual)0.01x
52-Week High$5.01
Operating Margin (5Y Avg)-1139.09%
EPS Excl Extra (Annual)$1.51
CapEx CAGR (5Y)-52.70%
26-Week Price Return30.18%
Quick Ratio (Annual)6.84x
13-Week Price Return8.80%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.45x
Enterprise Value$151.84M
Revenue / Share Growth (5Y)-13.06%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)9.17%
Revenue / Employee (Annual)$103,100
Pretax Margin (Annual)379.70%
Cash / Share (Annual)$3.21
3-Month Return Std Dev54.95%
Gross Margin (5Y Avg)78.65%
Net Income / Employee (TTM)$8,439,500
ROE (Last FY)32.07%
Net Interest Coverage (Annual)-0.46x
EPS Basic Excl Extra (Annual)$1.51
P/FCF (TTM)78.66x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$2.59
ROI (TTM)55.11%
P/S Ratio (TTM)43.31x
Pretax Margin (5Y Avg)108.79%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$3.84
Price vs S&P 500 (52W)48.19%
P/E Ratio (TTM)1.38x
EPS Growth TTM (YoY)60.34%
Year-to-Date Return30.18%
5-Day Price Return-4.63%
EPS Normalized (Annual)$1.51
ROA (5Y Avg)-2.24%
Net Profit Margin (Annual)412.31%
Month-to-Date Return-6.55%
Cash Flow / Share (TTM)$-0.42
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-1176.79%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-1.90%
P/E Excl Extra (TTM)1.38x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$2.59
P/TBV (Quarterly)0.59x
P/B Ratio (Annual)0.57x
Pretax Margin (TTM)-838.40%
Book Value / Share (Annual)$5.09
Price vs S&P 500 (13W)0.54%
Beta1.26x
P/FCF (Annual)35.12x
Revenue / Share (TTM)$0.00
ROE (TTM)55.11%
52-Week Low$1.98
vGradeC
gGradeD
mGradeB
vgmGradeC
Show chart for
Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ORMPOramed Pharmaceuticals Inc. | C | D | B | $3.71 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Oramed Pharmaceuticals develops proprietary oral delivery technology for therapeutic proteins, including insulin, designed to survive the stomach's harsh environment. The platform enables injectable biologics to be administered as oral medications, potentially improving patient convenience and compliance. Its clinical pipeline includes ORMD-0801 for diabetes and ORMD-0901.